Sydney medtech startup Oli raised $6.5 million in a Series A3 round to commercialise its maternal and fetal monitoring platform. Scale Investors, Clare Ventures, and the University of Sydney backed the round.
The raise brings total private capital to $13 million across three Series A tranches: $4.7 million in 2022, $1.8 million in 2024, and now $6.5 million. They have also pulled $9.5 million in non-dilutive grants.
Oli makes a wireless wearable that tracks maternal and fetal vitals during labour. The device captures data from 10 biosensors and runs it through predictive algorithms to flag complications before they escalate. Founded in 2018 by mechatronic engineer Dr Sarah McDonald, the company was previously called Baymatob.
What this means for sales teams
Oli is moving from product development into hospital procurement. That shift typically means:
- Clinical sales hires: expect AE and SDR roles targeting hospital systems
- Long sales cycles: hospital deals take 12 to 18 months, sometimes longer
- Comp structure: medtech sales OTE in ANZ runs $120k to $180k for experienced AEs, depending on deal size and territory
- Complex buying process: you are selling to clinical directors, procurement, IT, and risk management
The maternal health tech market is growing but still early. Competitors include traditional fetal monitoring incumbents (GE Healthcare, Philips) and newer predictive platforms. Differentiation will matter: hospitals do not buy on innovation alone, they buy on clinical outcomes and integration with existing workflows.
For sales professionals considering medtech: it is a different game than SaaS. Longer cycles, clinical validation requirements, and regulatory approvals. But once you land a hospital system, renewal rates are strong and expansion opportunities are real.
Oli has not publicly disclosed headcount or current sales team size. If you are tracking medtech opportunities in Sydney, this is one to watch as they scale commercial operations.